Quantifying the annual incidence and underestimation of seasonal influenza: A modelling approach.
Mathematical modelling
evidence synthesis
influenza
vaccine
Journal
Theoretical biology & medical modelling
ISSN: 1742-4682
Titre abrégé: Theor Biol Med Model
Pays: England
ID NLM: 101224383
Informations de publication
Date de publication:
10 07 2020
10 07 2020
Historique:
received:
07
03
2020
accepted:
28
05
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Seasonal influenza poses a significant public health and economic burden, associated with the outcome of infection and resulting complications. The true burden of the disease is difficult to capture due to the wide range of presentation, from asymptomatic cases to non-respiratory complications such as cardiovascular events, and its seasonal variability. An understanding of the magnitude of the true annual incidence of influenza is important to support prevention and control policy development and to evaluate the impact of preventative measures such as vaccination. We use a dynamic disease transmission model, laboratory-confirmed influenza surveillance data, and randomized-controlled trial (RCT) data to quantify the underestimation factor, expansion factor, and symptomatic influenza illnesses in the US and Canada during the 2011-2012 and 2012-2013 influenza seasons. Based on 2 case definitions, we estimate between 0.42-3.2% and 0.33-1.2% of symptomatic influenza illnesses were laboratory-confirmed in Canada during the 2011-2012 and 2012-2013 seasons, respectively. In the US, we estimate between 0.08-0.61% and 0.07-0.33% of symptomatic influenza illnesses were laboratory-confirmed in the 2011-2012 and 2012-2013 seasons, respectively. We estimated the symptomatic influenza illnesses in Canada to be 0.32-2.4 million in 2011-2012 and 1.8-8.2 million in 2012-2013. In the US, we estimate the number of symptomatic influenza illnesses to be 4.4-34 million in 2011-2012 and 23-102 million in 2012-2013. We illustrate that monitoring a representative group within a population may aid in effectively modelling the transmission of infectious diseases such as influenza. In particular, the utilization of RCTs in models may enhance the accuracy of epidemiological parameter estimation.
Sections du résumé
BACKGROUND
Seasonal influenza poses a significant public health and economic burden, associated with the outcome of infection and resulting complications. The true burden of the disease is difficult to capture due to the wide range of presentation, from asymptomatic cases to non-respiratory complications such as cardiovascular events, and its seasonal variability. An understanding of the magnitude of the true annual incidence of influenza is important to support prevention and control policy development and to evaluate the impact of preventative measures such as vaccination.
METHODS
We use a dynamic disease transmission model, laboratory-confirmed influenza surveillance data, and randomized-controlled trial (RCT) data to quantify the underestimation factor, expansion factor, and symptomatic influenza illnesses in the US and Canada during the 2011-2012 and 2012-2013 influenza seasons.
RESULTS
Based on 2 case definitions, we estimate between 0.42-3.2% and 0.33-1.2% of symptomatic influenza illnesses were laboratory-confirmed in Canada during the 2011-2012 and 2012-2013 seasons, respectively. In the US, we estimate between 0.08-0.61% and 0.07-0.33% of symptomatic influenza illnesses were laboratory-confirmed in the 2011-2012 and 2012-2013 seasons, respectively. We estimated the symptomatic influenza illnesses in Canada to be 0.32-2.4 million in 2011-2012 and 1.8-8.2 million in 2012-2013. In the US, we estimate the number of symptomatic influenza illnesses to be 4.4-34 million in 2011-2012 and 23-102 million in 2012-2013.
CONCLUSIONS
We illustrate that monitoring a representative group within a population may aid in effectively modelling the transmission of infectious diseases such as influenza. In particular, the utilization of RCTs in models may enhance the accuracy of epidemiological parameter estimation.
Identifiants
pubmed: 32646444
doi: 10.1186/s12976-020-00129-4
pii: 10.1186/s12976-020-00129-4
pmc: PMC7347407
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Références
N Engl J Med. 2014 Aug 14;371(7):635-45
pubmed: 25119609
Epidemiol Infect. 2014 May;142(5):955-63
pubmed: 24107289
Epidemiol Infect. 2007 Aug;135(6):951-8
pubmed: 17156502
Am J Public Health. 1981 Jun;71(6):643-5
pubmed: 7235106
Influenza Other Respir Viruses. 2013 Sep;7(5):799-808
pubmed: 23122189
Crit Care Med. 2014 Nov;42(11):2325-32
pubmed: 25148596
PLoS One. 2014 Nov 25;9(11):e113903
pubmed: 25423025
BMC Infect Dis. 2014 Sep 04;14:480
pubmed: 25186370
BMC Public Health. 2014 Feb 11;14:147
pubmed: 24517715
Influenza Other Respir Viruses. 2014 Sep;8(5):507-15
pubmed: 24975705
Clin Infect Dis. 2014 Feb;58(3):319-27
pubmed: 24235265
J Infect Dis. 2015 May 15;211(10):1529-40
pubmed: 25406334
J Infect Dis. 2014 Jul 1;210(1):126-37
pubmed: 24446529
Emerg Infect Dis. 2009 Dec;15(12):2004-7
pubmed: 19961687
Influenza Other Respir Viruses. 2008 Jan;2(1):1-8
pubmed: 19453488
Pediatr Infect Dis J. 2006 Sep;25(9):795-800
pubmed: 16940836
Math Biosci Eng. 2011 Jan;8(1):1-20
pubmed: 21361397
Stat Med. 2004 Nov 30;23(22):3469-87
pubmed: 15505892
Epidemiology. 2012 Nov;23(6):829-38
pubmed: 22992574
N Engl J Med. 2006 Jul 6;355(1):31-40
pubmed: 16822994
Influenza Other Respir Viruses. 2014 Jan;8(1):33-41
pubmed: 24209610
Epidemiology. 2015 Nov;26(6):862-72
pubmed: 26133025
Am J Epidemiol. 1997 Nov 15;146(10):789-803
pubmed: 9384199
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
Lancet Infect Dis. 2015 Mar;15(3):293-300
pubmed: 25672568
Emerg Infect Dis. 2015 Sep;21(9):1595-601
pubmed: 26292017
Infect Dis Model. 2017 Jun 29;2(3):288-303
pubmed: 29928743